Skip to content Skip to navigation

Defective Drugs

Acts Drug Packages

Actos became a worldwide, top-selling drug for treatment of Type II diabetes. But the complaint for this class action claims that it increases the risk of bladder cancer—and that the companies involved in developing and promoting the drug knew about this and concealed it. 

Actemra

Is Actemra a safe and effective drug for rheumatoid arthritis (RA) or does it pose risks of serious injury and even death that are not even listed among its side effects?

Elderly Eye

When you go for an eye treatment for worsening vision, you don’t expect the treatment to leave you blind in that eye. Yet for once the drug used for treatment doesn’t seem to be at fault, and we’re currently investigating what the problem might be.

image of cvs caremark logo

This class action lawsuit claims that CaremarkPCS Health does not have adequate policies and procedures to ensure that certain specialty drugs, including Enbrel, are maintained within the drugs’ required temperature range during storage and distribution, therefore reducing the quality of the drugs.

These lawsuits allege that Merck violated state law in the marketing of its drug Januvia as the company failed to warn of increased risk of pancreatic cancer.

These lawsuits allege that the manufacturer of the drug Xarelto failed to properly warn of risks of internal bleeding.

Insulin

Invokana, Invokamet, Jardiance, Xigduo XR,  Farxiga, and Glyxambi are drugs used to treat Type 2 diabetes. An investigation is now looking into possible connections between these drugs and a serious condition called ketoacidosis.

Onglyza Lawsuits

This mass tort investigation alleges that the diabetes drug Onglyza can raise the risk of pancreatic cancer in patients and cause heart failure and death. Onglyza is made by AstraZeneca and has been approved by the FDA for the treatment of Type 2 diabetes. 

These lawsuits allege that Zofran can cause undisclosed birth defects when a pregnant woman takes the drug.

These lawsuits allege that the manufacturer of Eliquis failed to properly disclose the risks of internal bleeding.